Menadione

Menadione
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gloria Picoy [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
NOTE: Most over the counter (OTC) are not reviewed and approved by the FDA. However, they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

Overview

Menadione is a polycyclic aromatic ketone that is FDA approved for the treatment of joint pains, bruising, fatigue, abdominal discomfort, diarrhea, and hay fever.. Common adverse reactions include {{{adverseReactions}}}.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

• For temporary relief of joint pains, bruising, fatigue, abdominal discomfort, diarrhea, and hay fever.

• Dosage: 1-10 drops under the tongue, 3 times a day

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Menadione in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Menadione in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Consult a physician for use in children under 12 years of age.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Menadione in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Menadione in pediatric patients.

Contraindications

There is limited information regarding Menadione Contraindications in the drug label.

Warnings

• If pregnant or breast-feeding, ask a health care professional before use.
• Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
• Do not use if tamper evident seal is broken or missing. Store in a cool, dry place.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Menadione Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Menadione Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Menadione Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Menadione in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Menadione in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Menadione during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Menadione in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Menadione in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Menadione in geriatric settings.

Gender

There is no FDA guidance on the use of Menadione with respect to specific gender populations.

Race

There is no FDA guidance on the use of Menadione with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Menadione in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Menadione in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Menadione in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Menadione in patients who are immunocompromised.

Administration and Monitoring

Administration

Oral

Monitoring

There is limited information regarding Menadione Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Menadione and IV administrations.

Overdosage

There is limited information regarding Menadione overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

Template:Chembox E numberTemplate:Chembox AppearanceTemplate:Chembox DensityTemplate:Chembox MeltingPtTemplate:Chembox BoilingPtTemplate:Chembox SolubilityInWaterTemplate:Chembox FlashPtTemplate:Chembox Lethal amounts (set)

Menadione

Ball-and-stick model
Names
IUPAC name 2-Methylnaphthalene-1,4-dione
Other names Menaphthone; Vitamin K3; β-Methyl-1,4-naphthoquinone; 2-Methyl-1,4-naphthodione; 2-Methyl-1,4-naphthoquinone
Identifiers
CAS Number	58-27-5 Y
3D model (JSmol)	Interactive image
ChEBI	CHEBI:28869 N
ChEMBL	ChEMBL590 Y
ChemSpider	3915 Y
DrugBank	DB00170 N
ECHA InfoCard
KEGG	D02335 Y
PubChem CID	4055
UNII	723JX6CXY5 Y
InChI InChI=1S/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H3 Y Key: MJVAVZPDRWSRRC-UHFFFAOYSA-N Y InChI=1/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H3 Key: MJVAVZPDRWSRRC-UHFFFAOYAY
SMILES O=C\2c1c(cccc1)C(=O)/C(=C/2)C
Properties
Chemical formula	C11H8O2
Molar mass	172.18 g·mol−1
Hazards
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YN ?)
Infobox references

Mechanism of Action

There is limited information regarding Menadione Mechanism of Action in the drug label.

Structure

There is limited information regarding Menadione Structure in the drug label.

Pharmacodynamics

There is limited information regarding Menadione Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Menadione Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Menadione Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Menadione Clinical Studies in the drug label.

How Supplied

Menadione 1 FL OZ (30 ml)

Storage

There is limited information regarding Menadione Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Menadione |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Menadione |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Menadione Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Menadione interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

• Menadione

Look-Alike Drug Names

There is limited information regarding Menadione Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

WikiDoc Resources for Menadione
Articles
Most recent articles on Menadione Most cited articles on Menadione Review articles on Menadione Articles on Menadione in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Menadione Images of Menadione Photos of Menadione Podcasts & MP3s on Menadione Videos on Menadione
Evidence Based Medicine
Cochrane Collaboration on Menadione Bandolier on Menadione TRIP on Menadione
Clinical Trials
Ongoing Trials on Menadione at Clinical Trials.gov Trial results on Menadione Clinical Trials on Menadione at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Menadione NICE Guidance on Menadione NHS PRODIGY Guidance FDA on Menadione CDC on Menadione
Books
Books on Menadione
News
Menadione in the news Be alerted to news on Menadione News trends on Menadione
Commentary
Blogs on Menadione
Definitions
Definitions of Menadione
Patient Resources / Community
Patient resources on Menadione Discussion groups on Menadione Patient Handouts on Menadione Directions to Hospitals Treating Menadione Risk calculators and risk factors for Menadione
Healthcare Provider Resources
Symptoms of Menadione Causes & Risk Factors for Menadione Diagnostic studies for Menadione Treatment of Menadione
Continuing Medical Education (CME)
CME Programs on Menadione
International
Menadione en Espanol Menadione en Francais
Business
Menadione in the Marketplace Patents on Menadione
Experimental / Informatics
List of terms related to Menadione

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]

Menadione is a polycyclic aromatic ketone, based on 1,4-naphthoquinone, with a 2-methyl substituent.

It was formerly sometimes called vitamin K₃, although derivatives of naphthoquinone without the sidechain in the 3-position cannot exert all the functions of the K vitamins. Menadione is a vitamin precursor of K₂ which utilizes alkylation in the liver to yield menaquinones (MK-n, n=1-13; K₂ vitamers), and hence, is better classified as a provitamin.

Despite the fact that it can serve as a precursor to various types of vitamin K, menadione is generally not used as a nutritional supplement. Large doses of menadione have been reported to cause adverse outcomes including hemolytic anemia due to G6PD deficiency, neonatal brain or liver damage, or neonatal death in some cases. Moreover, menadione supplements have been banned by the FDA because of their high toxicity. Menadione has been used experimentally as a chemotherapic agent for cancer, ca 1945, but has lost ground to much safer, human form, vitamin K₂ vitamers. Low level menadione is still used as an inexpensive micronutrient for livestock in many countries.

Lately, menadione has been mentioned again as a treatment for cancer in conjunction with vitamin C (See "The end of cancer" by April Kirkendoll) but modern researchers and trials are investigating nontoxic K₂ vitamers such as menaquinone-4^[4] in conjunction with more comprehensive regimens.

See also

• Vitamin K

de:Menadion

Template:WikiDoc Sources